PHVS Pharvaris N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1830487 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 29.61M | 23.07M | 14.68M | 13.72M | 8.06M |
| SG&A expense | 10.77M | 11.31M | 7.77M | 7.66M | 4.66M |
| Operating income | -45.28M | -29.66M | -21.80M | -9.88M | -15.20M |
| Income tax | 202,782 | 70,623 | 94,178 | 2.74M | 2,965 |
| Net income | -45.48M | -29.73M | -21.90M | -12.71M | -15.20M |
| EPS (basic) | -0.83 | -0.55 | -0.63 | -0.38 | -0.46 |
| EPS (diluted) | -0.83 | -0.55 | -0.63 | -0.38 | -0.46 |
| Weighted avg. shares (diluted) | 54.69M | 53.94M | 34.56M | 33.58M | 33.13M |
| Balance sheet | |||||
| Cash & equivalents | 199.57M | 343.57M | 179.19M | 201.38M | 224.32M |
| Receivables | 2.60M | 1.61M | 334,299 | 331,928 | — |
| PP&E, netmay include right-of-use assets (IFRS) | 719,994 | 258,551 | 220,138 | 141,846 | — |
| Total assets | 209.81M | 351.85M | 189.74M | 206.74M | — |
| Total liabilities | 25.47M | 19.08M | 16.01M | 16.17M | — |
| Shareholders' equity | 184.34M | 332.77M | 173.73M | 190.57M | 222.23M |
| Cash flow statement | |||||
| Operating cash flow | — | — | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.